Loading...

NovoCure

Nasdaq:NVCR
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NVCR
Nasdaq
$6B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • NovoCure has significant price volatility in the past 3 months.
NVCR Share Price and Events
7 Day Returns
3.2%
NasdaqGS:NVCR
3.1%
US Medical Equipment
2.2%
US Market
1 Year Returns
98.9%
NasdaqGS:NVCR
16.3%
US Medical Equipment
3.8%
US Market
NVCR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NovoCure (NVCR) 3.2% 13.2% 27% 98.9% 482.4% -
US Medical Equipment 3.1% 8.8% 5.9% 16.3% 68.2% 100.9%
US Market 2.2% 4.2% 4.4% 3.8% 43% 40.9%
1 Year Return vs Industry and Market
  • NVCR outperformed the Medical Equipment industry which returned 16.3% over the past year.
  • NVCR outperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
NVCR
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for NovoCure's competitors could be found in our database.

Value

 Is NovoCure undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NovoCure to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NovoCure.

NasdaqGS:NVCR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:NVCR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 20%) (2.86%))
0.914
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.914 * 5.96%)
8.18%

Discounted Cash Flow Calculation for NasdaqGS:NVCR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NovoCure is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:NVCR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.18%)
2019 32.00 Analyst x1 29.58
2020 120.85 Analyst x2 103.27
2021 188.00 Analyst x1 148.51
2022 270.60 Analyst x1 197.60
2023 363.20 Analyst x1 245.17
2024 440.51 Est @ 21.29% 274.88
2025 509.76 Est @ 15.72% 294.05
2026 570.03 Est @ 11.82% 303.96
2027 621.88 Est @ 9.1% 306.54
2028 666.56 Est @ 7.19% 303.73
Present value of next 10 years cash flows $2,207.30
NasdaqGS:NVCR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $666.56 × (1 + 2.73%) ÷ (8.18% – 2.73%)
$12,571.17
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,571.17 ÷ (1 + 8.18%)10
$5,728.28
NasdaqGS:NVCR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,207.30 + $5,728.28
$7,935.58
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,935.58 / 95.77
$82.86
NasdaqGS:NVCR Discount to Share Price
Calculation Result
Value per share (USD) From above. $82.86
Current discount Discount to share price of $59.87
= -1 x ($59.87 - $82.86) / $82.86
27.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NovoCure is available for.
Intrinsic value
28%
Share price is $59.87 vs Future cash flow value of $82.86
Current Discount Checks
For NovoCure to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NovoCure's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NovoCure's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NovoCure's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NovoCure's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:NVCR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.59
NasdaqGS:NVCR Share Price ** NasdaqGS (2019-06-21) in USD $59.87
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.58x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NovoCure.

NasdaqGS:NVCR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NVCR Share Price ÷ EPS (both in USD)

= 59.87 ÷ -0.59

-101.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NovoCure is loss making, we can't compare its value to the US Medical Equipment industry average.
  • NovoCure is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does NovoCure's expected growth come at a high price?
Raw Data
NasdaqGS:NVCR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -101.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
63.4%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NovoCure, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NovoCure's assets?
Raw Data
NasdaqGS:NVCR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.32
NasdaqGS:NVCR Share Price * NasdaqGS (2019-06-21) in USD $59.87
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.6x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.81x
NasdaqGS:NVCR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NVCR Share Price ÷ Book Value per Share (both in USD)

= 59.87 ÷ 1.32

45.33x

* Primary Listing of NovoCure.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NovoCure is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess NovoCure's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. NovoCure has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NovoCure expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NovoCure expected to grow at an attractive rate?
  • NovoCure's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • NovoCure's earnings growth is expected to exceed the United States of America market average.
  • NovoCure's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:NVCR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:NVCR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 63.4%
NasdaqGS:NVCR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 27%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:NVCR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:NVCR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,005 371 430 2
2022-12-31 801 278 283 2
2021-12-31 621 195 149 3
2020-12-31 474 125 65 6
2019-12-31 339 40 -15 6
NasdaqGS:NVCR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 269 11 -55
2018-12-31 248 -2 -64
2018-09-30 232 -22 -59
2018-06-30 217 -25 -59
2018-03-31 194 -23 -64
2017-12-31 177 -33 -62
2017-09-30 154 -44 -73
2017-06-30 125 -80 -95
2017-03-31 105 -104 -114
2016-12-31 83 -108 -132
2016-09-30 65 -120 -143
2016-06-30 52 -109 -135

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NovoCure's earnings are expected to grow significantly at over 20% yearly.
  • NovoCure's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:NVCR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from NovoCure Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:NVCR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.09 4.91 3.26 2.00
2022-12-31 2.72 2.95 2.48 2.00
2021-12-31 1.14 1.67 0.54 3.00
2020-12-31 0.53 0.97 0.15 6.00
2019-12-31 -0.25 -0.11 -0.41 5.00
NasdaqGS:NVCR Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.59
2018-12-31 -0.69
2018-09-30 -0.65
2018-06-30 -0.65
2018-03-31 -0.72
2017-12-31 -0.70
2017-09-30 -0.83
2017-06-30 -1.09
2017-03-31 -1.33
2016-12-31 -1.54
2016-09-30 -1.68
2016-06-30 -2.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NovoCure will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NovoCure's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NovoCure has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NovoCure performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NovoCure's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NovoCure does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare NovoCure's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NovoCure's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
NovoCure's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NovoCure Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:NVCR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 269.25 -54.99 158.23 56.51
2018-12-31 248.07 -63.56 151.12 50.57
2018-09-30 232.06 -58.87 143.32 45.59
2018-06-30 217.41 -58.68 136.95 41.79
2018-03-31 194.27 -64.34 130.92 39.80
2017-12-31 177.03 -61.66 122.64 38.10
2017-09-30 153.61 -72.89 115.24 36.53
2017-06-30 125.17 -95.02 112.22 37.49
2017-03-31 104.72 -114.45 108.47 39.43
2016-12-31 82.89 -131.85 106.86 41.47
2016-09-30 65.03 -142.61 107.62 43.84
2016-06-30 52.31 -135.00 96.35 43.82
2016-03-31 40.93 -123.75 84.96 45.27
2015-12-31 33.09 -111.58 72.73 43.75
2015-09-30 24.51 -101.57 59.88 44.09
2015-06-30 19.93 -93.87 52.97 43.16
2015-03-31 17.51 -85.84 49.17 40.78
2014-12-31 15.49 -80.68 45.23 40.38
2013-12-31 10.36 -77.37 33.01 34.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NovoCure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NovoCure has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NovoCure improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NovoCure's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NovoCure has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NovoCure's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NovoCure's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NovoCure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NovoCure's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NovoCure's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NovoCure Company Filings, last reported 2 months ago.

NasdaqGS:NVCR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 126.39 149.31 256.60
2018-12-31 112.26 149.36 245.88
2018-09-30 114.94 149.23 227.70
2018-06-30 112.08 149.20 218.96
2018-03-31 106.12 149.16 216.32
2017-12-31 113.56 97.47 183.31
2017-09-30 116.69 97.05 186.56
2017-06-30 117.55 96.77 184.38
2017-03-31 128.90 96.49 189.25
2016-12-31 142.35 96.42 219.63
2016-09-30 158.24 95.97 235.55
2016-06-30 186.65 23.29 200.85
2016-03-31 220.43 23.19 235.77
2015-12-31 250.82 23.35 269.42
2015-09-30 121.22 24.55 137.32
2015-06-30 144.31 24.54 163.50
2015-03-31 76.42 24.52 96.22
2014-12-31 97.88 0.32 102.61
2013-12-31 171.78 0.35 175.89
  • NovoCure's level of debt (118.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 118.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making NovoCure has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making NovoCure has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -70.1% per year.
X
Financial health checks
We assess NovoCure's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NovoCure has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NovoCure's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NovoCure dividends.
If you bought $2,000 of NovoCure shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NovoCure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NovoCure's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:NVCR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:NVCR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NovoCure has not reported any payouts.
  • Unable to verify if NovoCure's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NovoCure's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NovoCure has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NovoCure's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NovoCure afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NovoCure has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NovoCure's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Asaf Danziger
COMPENSATION $4,570,294
AGE 52
TENURE AS CEO 17.4 years
CEO Bio

Mr. Asaf Danziger has been the Chief Executive Officer and Director of Novocure Limited since 2002 and 2012 respectively and also serves as its President. Mr. Danziger joined NovoCure in 2002 with significant experience leading the development of innovative medical technologies in both corporate management and hands-on R&D positions. From 1998 to 2002 he served as the Chief Executive Officer at Cybro Medical Ltd., the Israeli subsidiary of Imagyn Medical Technologies (Irvine, CA). He has particular expertise leading multidisciplinary teams of engineers, scientists and physicians from initial concept design to commercial production. He has been a Director of Novocure Ltd since 2012. He served as a Director at NanoPass Technologies Ltd. He served as a Communications and Electronics Officer in the Israeli Defense Force. Mr. Danziger holds a B.Sc. in Material Engineering from Ben Gurion University of the Negev, Israel, where he specialized in Microelectronics and Biomedicine.

CEO Compensation
  • Asaf 's compensation has increased whilst company is loss making.
  • Asaf 's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the NovoCure management team in years:

9.4
Average Tenure
56
Average Age
  • The average tenure for the NovoCure management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Bill Doyle

TITLE
Executive Chairman
COMPENSATION
$5M
AGE
56

Asaf Danziger

TITLE
President
COMPENSATION
$5M
AGE
52
TENURE
17.4 yrs

Yoram Palti

TITLE
Founder & CTO
COMPENSATION
$283K
AGE
80
TENURE
19.4 yrs

Wilco Groenhuysen

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
60
TENURE
7.4 yrs

Pritesh Shah

TITLE
Chief Commercial Officer
COMPENSATION
$3M

Mike Ambrogi

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
55
TENURE
9.4 yrs

Ashley Cordova

TITLE
Vice President of Finance & Investor Relations

Todd Longsworth

TITLE
Chief Compliance Officer & General Counsel
AGE
43

Ely Benaim

TITLE
Chief Medical Officer
AGE
57
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the NovoCure board of directors in years:

3.1
Average Tenure
59
Average Age
  • The tenure for the NovoCure board of directors is about average.
Board of Directors

Bill Doyle

TITLE
Executive Chairman
COMPENSATION
$5M
AGE
56
TENURE
10.4 yrs

Asaf Danziger

TITLE
President
COMPENSATION
$5M
AGE
52
TENURE
7.4 yrs

Gabe Leung

TITLE
Vice Chairman
COMPENSATION
$417K
AGE
56
TENURE
7.7 yrs

Tony Vernon

TITLE
Lead Independent Director
COMPENSATION
$474K
AGE
62
TENURE
3.1 yrs

Sheri McCoy

TITLE
Director
COMPENSATION
$782K
AGE
59
TENURE
1.1 yrs

Jeri Hilleman

TITLE
Director
COMPENSATION
$701K
AGE
60
TENURE
0.9 yrs

Charles Phillips

TITLE
Independent Director
COMPENSATION
$457K
AGE
70
TENURE
7.4 yrs

Martin Madden

TITLE
Director
COMPENSATION
$625K
AGE
57
TENURE
2.1 yrs

David Hung

TITLE
Director
COMPENSATION
$777K
AGE
60
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • NovoCure individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Jun 19 Sell William Doyle Individual 30. May 19 30. May 19 -48,100 $53.07 $-2,552,523
31. May 19 Sell William Doyle Individual 29. May 19 29. May 19 -1,900 $53.10 $-100,881
10. May 19 Sell William Doyle Individual 09. May 19 09. May 19 -31,460 $47.37 $-1,490,386
09. May 19 Sell William Doyle Individual 07. May 19 07. May 19 -32,098 $47.67 $-1,530,112
07. May 19 Sell William Doyle Individual 06. May 19 06. May 19 -29,038 $48.07 $-1,395,915
X
Management checks
We assess NovoCure's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NovoCure has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Be Worried About Insider Transactions At NovoCure Limited (NASDAQ:NVCR)?

So shareholders might well want to know whether insiders have been buying or selling shares in NovoCure Limited (NASDAQ:NVCR). … View our latest analysis for NovoCure NovoCure Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the Executive Chairman, William Doyle, sold US$1.5m worth of shares at a price of US$47.67 per share. … While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign.

Simply Wall St -

Is NovoCure Limited's (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm?

While small-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with its market cap of US$4.3b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

An Intrinsic Calculation For NovoCure Limited (NASDAQ:NVCR) Suggests It's 41% Undervalued

by taking the expected future cash flows and discounting them to their present value. … This is done using the Discounted Cash Flow (DCF) model. … If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

Simply Wall St -

Do Institutions Own NovoCure Limited (NASDAQ:NVCR) Shares?

The big shareholder groups in NovoCure Limited (NASDAQ:NVCR) have power over the company. … NovoCure has a market capitalization of US$4.6b, so it's too big to fly under the radar. … We'd expect to see both institutions and retail investors owning a portion of the company.

Simply Wall St -

Did The Underlying Business Drive NovoCure's (NASDAQ:NVCR) Lovely 308% Share Price Gain?

In the last 3 years NovoCure saw its revenue grow at 58% per year. … In light of this attractive revenue growth, it seems somewhat appropriate that the share price has been rocketing, boasting a gain of 60% per year, over the same period. … It's always tempting to take profits after a share price gain like that, but high-growth companies like NovoCure can sometimes sustain strong growth for many years.

Simply Wall St -

Is NovoCure Limited's (NASDAQ:NVCR) CEO Pay Fair?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Asaf Danziger's Compensation Compare With Similar Sized Companies. … Our data indicates that NovoCure Limited is worth US$4.9b, and total annual CEO compensation is US$4.3m.

Simply Wall St -

Should You Be Worried About Insider Transactions At NovoCure Limited (NASDAQ:NVCR)?

So we'll take a look at whether insiders have been buying or selling shares in NovoCure Limited (NASDAQ:NVCR). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … In the last twelve months, the biggest single sale by an insider was when Vice Chairman Kinyip Leung sold US$1.2m worth of shares at a price of US$28.77 per share.

Simply Wall St -

When Will NovoCure Limited (NASDAQ:NVCR) Breakeven?

The US$3.1b market-cap company’s loss lessens since it announced a -US$61.7m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$58.9m, as it approaches breakeven. … As path to profitability is the topic on NVCR’s investors mind, I’ve decided to gauge market sentiment. … In this article, I will touch on the expectations for NVCR’s growth and when analysts expect the company to become profitable

Simply Wall St -

What Kind Of Shareholder Appears On The NovoCure Limited's (NASDAQ:NVCR) Shareholder Register?

The big shareholder groups in NovoCure Limited (NASDAQ:NVCR) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is NovoCure Limited's (NASDAQ:NVCR) CEO Being Overpaid?

In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). … How Does Asaf Danziger's Compensation Compare With Similar Sized Companies. … Our data indicates that NovoCure Limited is worth US$2.9b, and total annual CEO compensation is US$4m.

Simply Wall St -

Company Info

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase II pilot and Phase III pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

Details
Name: NovoCure Limited
NVCR
Exchange: NasdaqGS
Founded: 2000
$5,742,157,781
95,766,474
Website: http://www.novocure.com
Address: NovoCure Limited
No. 4 The Forum,
Second Floor,
Saint Helier,
JE2 4UF,
Jersey
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NVCR Ordinary Shares Nasdaq Global Select US USD 02. Oct 2015
DB 038 Ordinary Shares Deutsche Boerse AG DE EUR 02. Oct 2015
Number of employees
Current staff
Staff numbers
598
NovoCure employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 00:55
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/05/24
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.